EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access · CC BY-NC-ND 4.0

Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: A systematic review and meta-analysis

Daniel Isufi, Mikkel Bak Jensen, Nikolai Loft, Lone Skov, Jesper Elberling, Farzad Alinaghi

JAAD International · 2025-02 · 18 · 106-116

DOI: 10.1016/j.jdin.2024.09.012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JAAD International, 2025-02. Verfasst von Daniel Isufi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Janus kinase (JAK) inhibitors block pathways involved in inflammation and immune response, making JAK inhibitors useful in the treatment of various diseases. While the efficacy of these drugs has been proven in several studies, their safety profile needs to be further investigated. In this systematic review and meta-analysis, we examined the risk of infections during treatment with oral JAK inhibitors with no concomitant treatment compared to placebo in phase 2 and 3 randomized, placebo-controlled trials. The medical databases PubMed, Web of Science, and EMBASE were searched from inception through February 2024, yielding 13,567 nonduplicate articles, of which 69 were included in the final quantitative analysis. Overall, we found that treatment with oral JAK inhibitors was associated with an increased risk of infections compared to placebo across all indications (relative risk: 1.39 [95% CI: 1.096-1.76, P = .0067]) and in dermatologic indications (relative risk: 1.46 [95% CI, 1.10-1.93, P = .0097]). Remarkably, an increased risk of herpes zoster infections was found in dermatologic indications but not in nondermatologic indications. In conclusion, we identified a significantly increased risk of developing infections during treatment with oral JAK inhibitors compared to placebo across indications. In sub-analyses, we additionally found an increased risk of herpes zoster in dermatologic indications.

Schlagwörter

Stichwörter der Autor:innen

JAK inhibitorsJanus kinase inhibitorimmune-mediated diseasesinfectionsrandomized clinical trials

Autor:innen und Institutionen

  • Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.
  • National Allergy Research Centre, Department of Dermatology and Allergy, University of Copenhagen, Hellerup, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Zitieren

APA

Isufi, D., Jensen, M. B., Loft, N., Skov, L., Elberling, J., & Alinaghi, F. (2025). Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: A systematic review and meta-analysis. JAAD International, 18, 106-116. https://doi.org/10.1016/j.jdin.2024.09.012

Vancouver

Isufi D, Jensen MB, Loft N, Skov L, Elberling J, Alinaghi F. Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: A systematic review and meta-analysis. JAAD International. 2025;18:106-116. doi:10.1016/j.jdin.2024.09.012

BibTeX
@article{Isufi2025,
  author = {Isufi, Daniel and Jensen, Mikkel Bak and Loft, Nikolai and Skov, Lone and Elberling, Jesper and Alinaghi, Farzad},
  title = {Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: A systematic review and meta-analysis},
  journal = {JAAD International},
  year = {2025},
  volume = {18},
  pages = {106--116},
  doi = {10.1016/j.jdin.2024.09.012}
}
Kostenlos starten →